| 生物活性 |
Platycodin D2 is an orally active triterpenoid saponin found in Platycodon grandiflorum that induces mitophagy in cancer cells via NIX, thereby activating the P21/CyclinA2 pathway and promoting cellular senescence; it also induces mitochondrial dysfunction, enhances autophagy, inhibits hepatocellular carcinoma cell proliferation, exhibits antitumor activity against multiple cancer cell types, promotes the mRNA expression of T-bet, GATA-3, Th1 cytokines IL-2 and IFN-γ, and Th2 cytokines IL-4 and IL-10, enhances splenocyte proliferation, serves as a vaccine adjuvant with low hemolytic activity against rabbit erythrocytes, and inhibits breast cancer cell proliferation by inducing mitochondrial reactive oxygen species (ROS) production, incomplete autophagy, and ferroptosis, making it useful for cancer, inflammation, and immunology-related research. |
体外研究 (In Vitro) |
Platycodin D2 (1-100 μM; 48 h) 可特异性抑制 Huh-7、MHCC97H、HCCLM3、HepG-2、SK-Hep1 和 Huh-6 肝癌细胞的增殖,IC50 值为 10.2-12.7 μM,而对 THLE-2 和 L02 正常肝细胞无显著细胞毒性作用 (IC50 >200 μM)。 Platycodin D2 (10 μM; 48 h) 不会在 Huh-7 或 HCCLM3 肝癌细胞中显著诱导细胞凋亡。 Platycodin D2 (10 μM; 24-48 h) 可在 Huh-7 和 HCCLM3 肝癌细胞中诱导强烈的自噬,表现为 LC3 斑点形成增加、自噬流水平升高、自噬溶酶体形成以及自噬相关蛋白表达改变,且不影响凋亡相关蛋白。 Platycodin D2 (5, 10 μM; 48 h) 可诱导 Huh-7 和 HCCLM3 肝癌细胞发生线粒体功能障碍,具体表现为 ROS 生成增加、线粒体膜电位降低,以及通过 LC3 与受损线粒体共定位介导的选择性线粒体自噬。 Platycodin D2 (10 μM; 48 h) 可通过 NIX 诱导 HCCLM3 肝癌细胞发生线粒体自噬,因为沉默 NIX 可消除 PD2 对自噬、细胞活力、线粒体功能及下游 P21/CyclinA2 表达的作用。 Platycodin D2 (10 μM; 48 h) 可诱导 Huh-7 和 HCCLM3 肝癌细胞发生 G2/M 期阻滞与衰老,该效应可通过细胞周期分布改变、SASP 基因表达上调、衰老相关蛋白表达变化、β-半乳糖苷酶活性升高、Lamin B1 水平降低以及细胞核 γ-H2A.X 聚集得到证实。 Platycodin D2 (3.906-125 μg/mL; 30 min) 对 0.5%兔红细胞悬液具有溶血活性,其 HD50 为 18.57 μg/mL。 Platycodin D2 (0.0016-1.0 μg/mL; 16 h) 可显著增强刀豆蛋白 A (Con A) 刺激的 ICR 小鼠初始脾细胞中 Th1 型 (IL-2、IFN-γ、T-bet) 和 Th2 型 (IL-4、IL-10、GATA-3) 细胞因子及转录因子的 mRNA 表达。 Platycodin D2 (5-50 μM; 48 h) 可强效抑制 MCF7、SKBR3 和 Hs578T 乳腺癌细胞的增殖,孵育 48 h 后其 IC50 值分别为 14.62 μM、29.60 μM 和 5.24 μM。 Platycodin D2 (5-50 μM; 48 h) 可通过上调 LC3II/I 与 p62 的表达、下调 Syntaxin 17、SNAP29、VAMP8 及 Lamp2b 的表达,在孵育 48 h 后阻断 MCF7、SKBR3 和 Hs578T 乳腺癌细胞中的自噬流。 Platycodin D2 (5-50 μM; 48 h) 可通过孵育 48 h 后下调 SLC7A11, GSH 和 GPX4 的水平,诱导 MCF7、SKBR3 和 Hs578T 乳腺癌细胞发生铁死亡。 Platycodin D2 (5-50 μM; 48 h) 可升高 MCF7、SKBR3 和 Hs578T 乳腺癌细胞内的亚铁离子水平,这是铁死亡的标志性特征。 Platycodin D2 (5-50 μM; 48 h) 可上调 MCF7、SKBR3 和 Hs578T 乳腺癌细胞中线粒体外膜蛋白 TOM20 的表达,提示线粒体损伤。 Platycodin D2 (5-50 μM; 48 h) 可升高 MCF7、SKBR3 和 Hs578T 乳腺癌细胞内的 MDA 水平,提示与铁死亡相关的脂质过氧化作用增强。 Platycodin D2 (5-50 μM; 48 h) 可降低 MCF7、SKBR3 和 Hs578T 乳腺癌细胞内的 SOD 水平,从而削弱抗氧化能力并促进铁死亡。 Platycodin D2 (5-50 μM; 48 h) 可在孵育 48 h 后提升 MCF7、SKBR3 和 Hs578T 乳腺癌细胞中的线粒体 ROS 生成并降低线粒体膜电位,进而造成线粒体损伤。
Cell Viability Assay
| Cell Line: |
Huh-7, MHCC97H, HCCLM3, HepG-2, SK-Hep1, Huh-6 hepatocellular carcinoma (HCC) cells, THLE-2, L02 normal liver cells |
| Concentration: |
1, 5, 10, 20, 50, 100 μM |
| Incubation Time: |
48 h |
| Result: |
Significantly reduced viability of all tested HCC cell lines, with IC50 values of 10.2 μM (Huh-7), 11.5 μM (MHCC97H), 10.4 μM (HCCLM3), 11.2 μM (HepG-2), 12.7 μM (SK-Hep1), and 11.8 μM (Huh-6). Had no obvious inhibitory effect on normal THLE-2 and L02 liver cells, with IC50 values >200 μM for both. |
Cell Autophagy Assay
| Cell Line: |
Huh-7, HCCLM3 HCC cells |
| Concentration: |
10 μM |
| Incubation Time: |
24 h; 48 h |
| Result: |
Significantly increased the number of EGFP-LC3 puncta per cell (20 puncta for HCCLM3, 60 puncta for Huh-7, compared to near-zero in controls). Showed significantly more red fluorescence than green fluorescence via mRFP-GFP-LC3 staining, indicating increased autophagic flux. Revealed abundant autophagolysosomes in PD2-treated cells via transmission electron microscopy. Increased LC3-II and Beclin 1 expression, and decreased P62 expression via Western blotting, while apoptosis-related proteins (Cleaved-caspase3, PARP, Cleaved-PARP) showed no significant changes. |
Cell Cycle Analysis
| Cell Line: |
Huh-7, HCCLM3 HCC cells |
| Concentration: |
10 μM |
| Incubation Time: |
48 h |
| Result: |
Induced G2/M phase arrest in HCC cells, with G2/M phase percentage increasing. Showed significant upregulation of SASP genes (IL-6, IL-8, MMP3, TGF-β, IGFBP3, CXCL-1) in both cell lines via Real Time qPCR. Revealed upregulated P21 and γ-H2A.X, and downregulated CDK1, CyclinA2, E2F, and p-RB via Western blotting. Showed a significant increase in β-galactosidase positive cells, reduced Lamin B1 fluorescence and nuclear aggregation of γ-H2A.X in PD2-treated cells via β-galactosidase staining and immunofluorescence. |
Western Blot Analysis
| Cell Line: |
MCF7, SKBR3, Hs578T |
| Concentration: |
5, 10, 20 μM (MCF7, Hs578T); 25, 50 μM (SKBR3) |
| Incubation Time: |
48 h |
| Result: |
Upregulated the expression of LC3II/I and p62 proteins in all three breast cancer cell lines. Downregulated the expression of Syntaxin 17, SNAP29, VAMP8, and Lamp2b proteins in all three breast cancer cell lines.\nDownregulated the expression of ferroptosis-related proteins SLC7A11 and GPX4 in all three breast cancer cell lines.\nSignificantly upregulated the expression of TOM20 in all three breast cancer cell lines. |
|
体内研究 (In Vivo) |
Platycodin D2 (5-10 mg/kg;瘤内注射;每 3 天 1 次;共 4 次给药) 可在雌性 BALB/c 裸鼠体内以剂量依赖方式显著抑制 HCC 肿瘤生长,其中 10 mg/kg 剂量可实现肿瘤体积近乎完全缩小,并通过上调 LC3-II、NIX 与 P21 及下调 Cyclin A2 诱导线粒体自噬与细胞衰老。 Platycodin D2 (25-100 μg;皮下注射;第 1 天和第 15 天) 可在 OVA (MS-Q48215) 免疫的 ICR 小鼠中诱导平衡的 Th1 和 Th2 免疫应答,在测试剂量下显著增强脾细胞增殖及 OVA 特异性抗体滴度。 Platycodin D2 (2.5-5 mg/kg;灌胃;每 2 天 1 次;共给药 5 次) 可显著抑制裸鼠体内乳腺癌肿瘤的生长,其中 5 mg/kg 剂量可使肿瘤体积减少 80.5%,其作用机制为阻断自噬流并诱导铁死亡。
| Animal Model: |
BALB/c nude mice (female, 5-6 weeks old, injected with 5×106 HCCLM3 cells in the right limb) |
| Dosage: |
5 mg/kg; 10 mg/kg |
| Administration: |
intratumoral injection; once every 3 days; 4 doses |
| Result: |
Significantly inhibited tumor growth compared to the control group. Reduced mean tumor volume to ~100 mm3 by week 4 at 5 mg/kg dose. Reduced mean tumor volume to near 0 mm3 by week 4 at 10 mg/kg dose. Maintained higher body weights than the control and 5-FU groups throughout the study. Dose-dependently increased mean density of LC3-II, NIX, and P21 in tumor tissues. Dose-dependently decreased mean density of Ki67 and Cyclin A2 in tumor tissues. |
| Animal Model: |
OVA-immunized ICR mice (female, 6 weeks old, 18-22 g) |
| Dosage: |
25 μg; 50 μg; 75 μg; 100 μg |
| Administration: |
s.c.; on Day 1 and Day 15 |
| Result: |
Significantly increased Con A- and LPS-stimulated splenocyte proliferation at 25 μg and 50 μg compared to the OVA control group (P<0.01 or P<0.001). Significantly enhanced OVA-induced splenocyte proliferation at all four tested doses compared to the OVA control group (P<0.05 or P<0.01). Significantly enhanced serum OVA-specific IgG, IgG1, IgG2a, and IgG2b antibody titers at all four tested doses compared to the OVA control group (P<0.01 or P<0.001). Resulted in significantly higher IgG and IgG1 titers at 75 μg and 100 μg than the Alum-treated group (P<0.05). |
| Animal Model: |
BALB/c nude mice (female, 4-5 weeks old, subcutaneous MCF7 cell implantation tumor-bearing model) |
| Dosage: |
2.5 mg/kg; 5 mg/kg |
| Administration: |
p.o.; once every 2 days; 5 total doses |
| Result: |
Reduced tumor volume by 80.5% at 5 mg/kg compared to control. Reduced tumor volume by 65.8% at 2.5 mg/kg compared to control. Did not affect mouse body weight. Downregulated ferroptosis-related proteins SLC7A11 and GPX4 in tumor tissues. Upregulated autophagy-related proteins LC3II and p62 in tumor tissues. Increased ROS levels in tumor tissues. Increased lipid peroxidation in tumor tissues. |
|